Strategic partnerships Sio Gene Therapies has a history of collaborations with leading organizations (such as Invitae) to advance genetic testing and patient access. Target BD efforts could focus on expanding partnerships with genetic testing labs, patient advocacy groups, and academic institutions to broaden trial recruitment, reduce screening friction, and accelerate commercialization paths.

Clinical pipeline leverage With a portfolio including GM1 and GM2 gangliosidosis programs and expanding into prevalent conditions like Parkinson’s disease, there is an opportunity to pitch co-development, research collaborations, or sponsored studies with biopharma, contract research organizations, and universities to share risk, access broader patient populations, and unlock additional funding channels.

Regulatory and manufacturing Given ongoing clinical activities and manufacturing/regulatory updates for AXO-Lenti-PD and AXO-AAV programs, there is room to offer specialized regulatory affairs, quality systems support, or contract manufacturing services to streamline clinical trials and future commercialization milestones.

Infrastructure readiness Sio’s tech stack and cloud-based operations indicate reliance on scalable IT and data platforms. Solutions for data management, security, and collaboration (e.g., compliant cloud services, analytics, and project management tooling) could help optimize trial data workflows and cross-functional coordination with partners.

Funding and scale With substantial funding and mid-sized employee base, Sio may seek strategic investors, grant programs, or milestone-based partnerships to finance expansion of late-stage trials and manufacturing capacity. Outreach could emphasize co-investment opportunities and risk-sharing models to accelerate time-to-patient access.